Press Releases

Δ 12.21.10   Mentor Capital Extends Funding to Leading-Edge Cancer Therapy Companies  

Δ 12.07.10    Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science

Δ  11.24.10  Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval

Δ 04.26.10 MNTR Sees Shift To Public Acceptance

Δ 03.23.10  Cancer Index at New High with 12 Yr Exclusive Period in Health Bill

Δ 03.01.10  Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index

Δ 01.19.10 MNTR Invests in 10 Cancer Index Companies

Δ 01.11.10  MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund

Δ  12.14.09 2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR

Δ  11.25.09 University Agreement Indicates Broad Cancer Application for QI Treatment

Δ  11.09.09 New Lab, Filings and JV Talks

Δ  09.30.09 MNTR Presents In NYC

Δ  07.15.09 Start of FDA Trials

Δ  07.15.09 QI Announces MNTR

Δ 07.10.09 MNTR Acquires First 20% of QI

Δ  09.06.08 MNTR Calls $3 Million Tranche

Δ  09.02.08 MNTR Initiates Trading